Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2023-11-30 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Regulatory Filings
2023-11-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2023-11-30 English
News release - English.pdf
Regulatory Filings
2023-11-29 English
Report of exempt distribution (45-106F1) (amended).pdf
Regulatory Filings
2023-11-21 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the commencement of a non-brokered private placement financing by Theralase Technologies Inc. It details the terms of the offering, use of proceeds, and termination of a previously announced financing. There are no financial statements, detailed financial performance data, or management discussion of results. The content focuses on capital raising activities and financing terms. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing, not just an announcement of a report or a regulatory filing. Hence, the classification is CAP with high confidence.
2023-11-17 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the commencement of a non-brokered private placement financing by Theralase Technologies Inc. It details the terms of the offering, use of proceeds, and termination of a previously announced financing. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is focused on capital raising activity and financing updates. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing, not just a brief announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2023-11-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.